Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03898479 · ClinicalTrials.gov registry record · Phase 2
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
A Phase 2 study of Alopecia Areata, sponsored by Sun Pharmaceutical Industries.
- Active
- Registry status
- Phase 2
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT03898479 is a Phase 2 study of Alopecia Areata that is active but no longer recruiting, run by Sun Pharmaceutical Industries. The registered enrollment target is 1,000 participants, below the 1,917-participant average among 26 other Alopecia Areata trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT03898479, a Phase 2 study of Alopecia Areata, is active but no longer recruiting, sponsored by Sun Pharmaceutical Industries.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
Conditions Studied
Interventions
- DRUG CTP-543
Study Locations (20)
California
- Kern Research Inc. - Bakersfield
- Hope Clinical Research - Canoga Park
- California Dermatology & Clinical Research Institute - Encinitas
- University of California, Irvine - Irvine
- Dermatology Research Associates - Los Angeles
- Quest Dermatology Research - Northridge
- Kaiser Permanente Northern California - Oakland - Oakland
- Palmtree Clinical Research, Inc. - Palm Springs
- Stanford University School of Medicine - Medical Dermatology Clinic - Redwood City
- Kaiser Permanente South Sacramento - Sacramento
- Kaiser Permanente Clinical Trials Unit - San Francisco
Arizona
- Alliance Dermatology & MOHS Center - Phoenix
- Center for Dermatology and Plastic Surgery/CCT Research - Scottsdale
Arkansas
- Johnson Dermatology - Fort Smith
- Northwest Arkansas Clinical Trials Center, PLLC - Rogers
Colorado
- Colorado Center for Dermatology, PLLC d/b/a CODerm Research - Centennial
- Colorado Medical Research Center - Denver
Alabama
- Total Skin and Beauty Dermatology Center - Birmingham
Connecticut
- Yale University Church Street Research Unit - New Haven
Florida
- Skin Care Research, LLC - Boca Raton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03898479
The ClinicalTrials.gov registry entry for NCT03898479 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,917-participant average among 26 other Alopecia Areata trials with a reported enrollment target (48% lower). The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 1 intervention - of which CTP-543 is the first listed.
NCT03898479 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03898479 about?
NCT03898479 is a clinical study titled "Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata". The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
What is the current status of trial NCT03898479?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,000 participants. The study started on 2019-04-04. Estimated completion is 2027-06.
What conditions does trial NCT03898479 study?
This clinical trial studies the following conditions: Alopecia Areata.
What interventions are being tested in trial NCT03898479?
The interventions under investigation include: CTP-543 (DRUG).
Who is sponsoring clinical trial NCT03898479?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03898479 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RECRUITING · Phase 2
-
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
RECRUITING · Phase 2
-
Regeneron AA Multicenter (Dupilumab)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.